Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical innovator advancing conditionally active biologic therapies for cancer treatment. This news hub provides investors and industry professionals with essential updates on the company’s proprietary CAB technology platform, clinical trial progress, and strategic developments.
Access timely press releases covering key milestones including regulatory filings, partnership announcements, and financial results. Our curated collection features updates on antibody-drug conjugate trials, intellectual property expansions, and operational developments across BioAtla’s global facilities.
This resource serves as your primary source for tracking BCAB’s progress in developing tumor-selective therapies. Bookmark this page for direct access to verified corporate communications and objective reporting on clinical advancements. Check regularly for updates on pipeline candidates and business strategy execution.
BioAtla, Inc. (Nasdaq: BCAB) reported progress in its clinical trials and financial results for Q4 and full-year 2022. The company has cleared dose-limiting toxicity (DLT) observation periods for its CAB-AXL therapy (BA3011) in multiple studies, with significant readouts expected in the second half of 2023. Cash reserves stood at $215.5 million, sufficient for operations into 2025. However, the net loss increased to $106.5 million for 2022. BioAtla anticipates several milestones, including FDA interactions and the initiation of several Phase 2 trials, demonstrating a strong commitment to advancing its product candidates aimed at high unmet medical needs.
BioAtla, a clinical-stage biotechnology company, will host a conference call on March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The company specializes in Conditionally Active Biologic (CAB) therapeutics aimed at treating solid tumors. This presentation will provide key business highlights and insights into its clinical programs, including two CAB candidates in Phase 2 trials.
Investors can access the results prior to the call on the company's website.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
